Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2012

View Archived Issues

New potential antibodies for anticancer use developed in U.S.

Potent novel ALK inhibitors presented

New dual allosteric Akt inhibitors show promise in cancer models

Antiglaucoma agent ATS-8535 characterized in vitro and in vivo

Novel HealOr product accelerates corneal healing

CNK1 PH domain investigated as a target for KRas-mutant cancer

Mitsubishi Tanabe Pharma reviews highlights of fiscal 2011

Research in U.K. links SNP to systemic sclerosis risk

Japanese phase II study of ONO-2745 completed

FDA committee votes on approval of Quad regimen

Phytopharm reports on preclinical Myogane study

Depomed receives milestone payment from Ironwood Pharmaceuticals

Kancera compounds show promise in cancer treatment

Theratechnologies' TH-1173 enters preclinical safety phase

Arno Therapeutics product obtains orphan drug status for NF2

New data presented on brentuximab vedotin in cutaneous T-cell lymphoma

Proximagen designs novel chemokine CXCR4 receptor antagonists

Novel OSM-directed antibodies created at Janssen Biotech

AstraZeneca presents new transient receptor potential TRPA1 channel antagonists

Research at Amicus yields new pharmacological chaperones

Novel candidate drugs for Alzheimer's disease patented

Islet Sciences licenses technology from Yale University

Galapagos kicks off new study of novel JAK1 inhibitor

Health Canada grants Apricus Biosciences meeting for nail fungus therapy

Mologen study meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...